logo
logo
AI

Discover the World’s Fastest Business Insights

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

Fujirebio Europe Receives Translational Research Funding From Alzheimer’S Drug Discovery Foundation For Development Of A Fully Automated Plasma Ptau181 Testing Solution

Fujirebio Europe Receives Translational Research Funding From Alzheimer’S Drug Discovery Foundation For Development Of A Fully Automated Plasma Ptau181 Testing Solution

10/28/21, 9:10 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/BE.svggent
H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator initiative of the Alzheimer's Drug Discovery Foundation (ADDF) to accelerate the development of a plasma pTau181 detection assay on the fully automated LUMIPULSE® G immunoassay platform. pTau is recognized as an important fluid biomarker linked to the diagnosis of Alzheimer’s disease (AD). The ADDF Diagnostics Accelerator initiative is part of a collaboration with Gates Ventures and other philanthropic partners.

Company Info

Company
Fujirebio
Location
gent, east flanders, belgium
Additional Info
Fujirebio is a global leader in the field of in vitro diagnostics (IVD) testing with more than 50 years’ experience in the conception, development, production and worldwide commercialization of robust IVD products. These span the range from specialized testing to fully automated routine clinical laboratory testing solutions covering a variety of disease states.

Company news

Wed, 25 Sep 2024 07:00:00 GMT

Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease - Business Wire

Mon, 23 Dec 2024 08:00:00 GMT

Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases - Business Wire

Mon, 15 Jul 2024 07:00:00 GMT

AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Milestone Achievement to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration - Yahoo Finance

Tue, 12 Mar 2024 07:00:00 GMT

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics - PR Newswire

Wed, 14 Feb 2024 08:00:00 GMT

Abbott and Fujirebio work on neurological biomarker assay for researchers - Medical Design & Outsourcing

Fri, 26 Jul 2024 07:00:00 GMT

Fujirebio Launches the Fully Automated Lumipulse® G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu - Yahoo Finance

Wed, 11 Sep 2024 07:00:00 GMT

Agappe Diagnostics, Fujirebio Holdings forge alliance to develop diagnostic tools - BusinessLine

Tue, 18 Jul 2023 07:00:00 GMT

Beckman Coulter, Fujirebio partner on gold rush for Alzheimer's blood tests - Fierce Biotech

Mon, 17 Jul 2023 07:00:00 GMT

Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test - PR Newswire

Wed, 08 Mar 2023 08:00:00 GMT

AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Strategic Partnership to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration - Business Wire

G2 High Performer Badge

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.